Buy 99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5 , 99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5 Suppliers, Manufacturers, Traders










You Are In: Home / Chemical Categories / 99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5 Suppliers

99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5 Suppliers

99% female steroids hormone flibanserin for gaining women sexy-enhancement 167933-07-5

Welcome to inquiry!

Email: tony@kafenbio.com

WhatsApp: +8618002259573

Skype: tony_14616

www.pharmhormone.com

 
99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5
 
Flibanserin Basic Info:
 
Product Name: Flibanserin
Chemical Name: Centrophenoxine HCL
CAS Number: 167933-07-5
EINECS Number: 222-975-3
Molecular Formula: C20H21F3N4O
Molecular Weight: 294.17
Melting Point: 139-143°C
Assay: 99.5%
Appearance: White powder
 
Flibanserin Description:
 
Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
 
Flibanserin Application:
 
Flibanserin is being hailed as "Viagra for women." The experimental drug - designed for post-menopausal women with low sex drives - has now won approval from an advisory panel for the Food and Drug Administration (FDA).
 
Flibanserin is an antidepressant that failed to help depression in clinical trials, but was noted to have improved sexual health outcomes. It's not uncommon for a drug to be developed for one purpose, then approved for another. Sildenafil (Viagra) was originally developed to lower blood pressure, but failed those trials. The benefit of both of these drugs was discovered by accident. However, flibanserin has now been studied for its effects on sexual health for nearly a decade.
 
Flibanserin doesn't have any interactions with hormonal medications, Thorp says. It does seem to interact with the original libido helper, though: some panelists recommended a warning against drinking alcohol while taking it, Reuters reported. (Interested in natural alternatives to hormone replacement therapy? The Natural Menopause Solution has everything you need to tame symptoms and trigger rapid, healthy weight loss in menopausal women.)
 
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to
a complex interplay of these factors.
 
Flibanserin Function:
 
A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin.(The FDA usually follows the recommendations of its expert panels.) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't "particularly compelling."
 
CAS Number:167933-07-5

Guangzhou Kafen Biotech Co.,Ltd.

No.128,Hanxing East Rd, Zhongcun, Panyu District, Guangzhou, Guangdong, China, guangzhou, china

china china

99% 99%
99% female steroids hormone flibanserin for gaining women sexy-enhancement 167933-07-5

Welcome to inquiry!

Email: tony@kafenbio.com

WhatsApp: +8618002259573

Skype: tony_14616

www.pharmhormone.com

 
99% Female Steroids Hormone Flibanserin For Gaining Women Sexy-Enhancement 167933-07-5
 
Flibanserin Basic Info:
 
Product Name: Flibanserin
Chemical Name: Centrophenoxine HCL
CAS Number: 167933-07-5
EINECS Number: 222-975-3
Molecular Formula: C20H21F3N4O
Molecular Weight: 294.17
Melting Point: 139-143°C
Assay: 99.5%
Appearance: White powder
 
Flibanserin Description:
 
Flibanserin is a novel, non-hormonal drug that has been studied in clinical trials for the treatment of HSDD in premenopausal and postmenopausal women. The application submitted to the FDA is for premenopausal women. Flibanserin is believed to work on key neurotransmitters, or chemicals, in the brain that affect sexual desire. More specifically, it is thought that flibanserin corrects an imbalance of levels of these neurotransmitters by increasing dopamine and norepinephrine (both responsible for sexual excitement) and decreasing serotonin (responsible for sexual inhibition). In clinical studies, flibanserin was evaluated for its ability to increase the frequency of satisfying sexual events, increase the intensity of sexual desire and decrease the associated distress women feel from its loss.
 
Flibanserin Application:
 
Flibanserin is being hailed as "Viagra for women." The experimental drug - designed for post-menopausal women with low sex drives - has now won approval from an advisory panel for the Food and Drug Administration (FDA).
 
Flibanserin is an antidepressant that failed to help depression in clinical trials, but was noted to have improved sexual health outcomes. It's not uncommon for a drug to be developed for one purpose, then approved for another. Sildenafil (Viagra) was originally developed to lower blood pressure, but failed those trials. The benefit of both of these drugs was discovered by accident. However, flibanserin has now been studied for its effects on sexual health for nearly a decade.
 
Flibanserin doesn't have any interactions with hormonal medications, Thorp says. It does seem to interact with the original libido helper, though: some panelists recommended a warning against drinking alcohol while taking it, Reuters reported. (Interested in natural alternatives to hormone replacement therapy? The Natural Menopause Solution has everything you need to tame symptoms and trigger rapid, healthy weight loss in menopausal women.)
 
HSDD is the most commonly reported form of female sexual dysfunction. HSDD is defined as a persistent or recurrent deficiency or absence of sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty, and which is not better accounted for by a medical, substance-related, psychiatric (e.g., depression) or other sexual condition. The cause of HSDD is believed to involve a multitude of social, psychological and biological factors and may be attributed to
a complex interplay of these factors.
 
Flibanserin Function:
 
A new drug designed to boost sexual desire in women is controversial for some and eagerly awaited by others, but it's hit a potentially serious snag. The drug didn't boost women's desire any more than a placebo in two clinical trials. The Food and Drug Administration posted the clinical trial results on its website today in advance of a committee meeting on Friday, when a panel of experts will vote whether or not to recommend approval of the drug called flibanserin.(The FDA usually follows the recommendations of its expert panels.) Although there was a slight increase in the number of sexually satisfying events flibanserin users had each month, the FDA staff who reviewed the results said the so-called response rate isn't "particularly compelling."
 
CAS Number:167933-07-5